Issue No. 49, Sep 2025Electronic ISSN 2521-3881 |
||
| Issue No. 49 - Sep2025 | ||
| 7-15 | Survival Outcomes of Penile Cancer Patients undergoing Primary Surgery: Experience from a Tertiary Cancer Care Centre in South India | |
|
Ricky Koshy Benjamin,1,4 Sivaranjith J1, Madhu Muralee1, Aswin Kumar2, Jagathnath Krishna K. M3 1Department of Surgical Oncology, Regional Cancer Centre, Thiruvananthapuram, India 2 Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, India 3 Department of Cancer Epidemiology and Biostatistics, Regional Cancer Centre, Thiruvananthapuram, India 4 Department of General Surgery, Government Medical College, Thiruvananthapuram, India | ||
| Abstract | ||
|
Introduction : Historically, the management of inguinal nodes in node-negative carcinoma penis has been a topic of debate. The chance of harboring micrometastasis in inguinal nodes in clinically node-negative patients is up to 25%. Dynamic sentinel node biopsy and elective inguinal lymph node dissection have flaws of false negativity and morbidity.
Methodology: This is a retrospective study on patients with carcinoma penis treated between January 2010 and August 2019 who underwent upfront surgery for the disease. Patients who were clinically and radiologically node-negative underwent surgery for the primary disease only, and were kept under follow-up for nodal recurrence, while those with suspicious nodes clinically or radiologically underwent inguinal node dissection.
Results: 77 patients were included in the study. Of the 50 patients who were clinically and radiologically nodenegative and did not undergo nodal dissection or invasive nodal staging, 21 had recurrence. Of the 27 patients who had node dissection, 16 were pathologically negative. Nine out of 16 patients with pathologically node-negative and seven out of 11 patients with pathologically node positive disease had recurrence. The median Overall survival (OS) and the median Recurrence free survival (RFS) were 77 and 75 months, respectively. The median OS in nodal observation and pathologically nodenegative group were 92 and 79 months, respectively (p- 0.266). The median RFS in nodal observation and pathologically node-negative group were 90 and 74 months, respectively (p- 0.182).
Conclusions : Our series shows that in properly evaluated clinically and radiologically node negative patients kept under observation, OS and RFS are comparable with pathologically node-negative patients, opening a window for nodal observation, thus avoiding morbidities of ilioinguinal block dissection or invasive nodal staging.
Keywords: Carcinoma penis, Survival, Recurrence, Nodal dissection.
|
||
| full article | ||
| 2 | 16-21 |
Incidental Radiation Exposure to the Internal Mammary Lymph Nodes in Breast Cancer Patients Undergoing Intensity-Modulated Radiation Therapy: A Retrospective Analysis |
|
Vishwadeep Mishra1, Shashank Shekhar2, Sudeep Bisht3, Rachita Chatterjee4, Laxman Pandey5, Archana Pandey6 1 Assistant Professor, Department of Radiation Oncology, All India Institute Of Medical Sciences, Gorakhpur, Uttar Pradesh, India 2 Associate Professor, Department of Radiation Oncology, All India Institute Of Medical Sciences, Gorakhpur, Uttar Pradesh, India 3 Assistant Professor, Department of Radiation Oncology, Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh, India 4 Assistant Professor, Department of Pediatrics, BRD Medical College, Gorakhpur, Uttar Pradesh, India 5 Associate Professor, Department of Radiation Oncology, Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh, India 6 Medical Physicist, Department of Radiation Oncology, Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh, India | ||
| Abstract | ||
|
Background : Breast cancer (BC) remains the most common malignancy among Indian women, with Stage III being the most frequent at diagnosis. While radiation therapy (RT) plays a pivotal role in the adjuvant treatment of breast cancer, the inclusion of internal mammary lymph nodes (IMLNs) in the radiation field remains controversial due to potential cardiopulmonary toxicity. However, the extent of incidental radiation to the IMLNs, especially with forward planning intensity-modulated radiation therapy (IMRT), remains under-explored. Objective :This study aimed to evaluate the incidental radiation dose received by the IMLNs in patients with leftsided breast cancer treated with forward planning IMRT.
Materials and Methods : A total of 36 left-sided breast cancer patients, aged 35-60 years, who underwent modified radical mastectomy followed by adjuvant RT using IMRT, were retrospectively analyzed. CT-based planning and contouring were performed according to RTOG guidelines, with IMLNs contoured retrospectively using Jetwa et al.'s method. Dosimetric parameters for the planning target volume (PTV) and IMLNs were extracted and analyzed using dose-volume histograms. Statistical comparisons were made using the dependent Student's t-test.
Results: The PTV received effective radiation coverage with a mean D95 of 38.47 Gy and a mean Dmean of 40.10 Gy. The IMLNs, although not directly targeted, received significant incidental radiation, with a mean D95 of 8.49 Gy, D50 of 21.59 Gy, and Dmean of 21.40 Gy. The maximum dose to the IMLNs (Dmax) reached 38.14 Gy. Comparative analysis revealed statistically significant differences in both Dmax and Dmean between PTV and IMLNs (p = 0.004 and p < 0.001, respectively).
Conclusion: Forward planning IMRT provides substantial incidental radiation exposure to the IMLNs, which may have therapeutic implications in reducing recurrence risk. However, this exposure also necessitates careful consideration of potential long-term toxicities to adjacent organs. Further prospective studies are warranted to evaluate the clinical outcomes associated with incidental IMLN irradiation.
|
||
| full article | ||
| 3 | 22-27 | Safety and Outcome Analysis of Preoperative chemoradiation in Esophageal carcinoma |
|
Shuchita Pathak 1, Santhosh KD2, Parikshith J3, Rasmi Palassery2, Vinayak V Maka2 1 Dayanand Medical College & Hospital, Ludhiana, Punjab, INDIA 2 MS Ramaiah Medical College, Bengaluru, Karnataka, INDIA 3 Mohandai Oswal Hospital, Ludhiana, Punjab, INDIA
| ||
| Abstract | ||
|
Background: The incidence of esophageal cancer (EC) is increasing now-a-days and the management of EC has changed dramatically with the widespread adoption of mixed modality therapy. Although many Indian centres use combined modality therapy with neoadjuvant chemoradiation (nCRT), published data are scarce. This study assessed the feasibility of trimodality therapy in terms of safety and pathological complete response (pCR) among newly diagnosed patients with EC. Patients and Methods: This ambispective study included the retrospective data of patients with locally advanced resectable carcinoma of the middle and lower thoracic oesophagus who were diagnosed and treated between January 2018 and December 2020 along with the prospective data of patients who were diagnosed between January 2021 and January 2023. The clinicodemographic details, radiation technique delivered along with the total dose planned, the dose received and chemotherapy details along with haematological toxicities and non-haematological toxicities were noted. The surgical details and aspects such as the interval between completion of neoadjuvant chemoradiation and surgery, postoperative mortality, pulmonary and cardiac complications, anastomotic leaks and length of hospital stay were recorded. The main outcome was the pCR of patients who received nCRT and underwent surgery. Results: Out of 250 cases retrieved, 100 eligible cases were included, in that, 50 patients received nCRT. About 84% of them underwent surgery after receiving nCRT and 30 patients (60%) post-surgery develop pCR. There were no grade 3 or 4 haematological toxicity noted and only few pateints developed non-haematological toxicities. Also, 16 patients developed postoperative complications. The median follow-up was 24 months, and the 1-year overall survival rate was 62 % among patients who received nCRT followed by surgery. Conclusion: Neoadjuvant chemoradiotherapy followed by surgery was tolerable and safe in the majority of patients with locally advanced EC with lower incidence of Grade 3 and 4 haematological, non-haematological toxicity and post-surgical complications. Keywords: Esophageal cancer, Neoadjuvant chemoradiotherapy, trimodality therapy, pathological complete response, haematological toxicities
|
||
| full article | ||
| 4 | 28-34 |
Impact of size of ovoids with Intra-cavitary Brachytherapy on dose to point A in patients with Cancer Cervix |
|
Dr. Tanvir Pasha, Dr. Nikhila Radhakrishna, Dr. Rekha Reddy Buchapudi, Dr. Saritha Sunny Pullan, Dr. Hamsini R S, Dr. Elna Jerod, Dr. Naveen Thimmaiah, Dr. Sridhar Poojar, Dr. Uday Krishna, Dr. Siddanna Rudrappa Palled, Dr. Thejaswini B, Dr. Lokesh Viswanath Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka 560029, INDIA
| ||
| Abstract | ||
|
Background : Intracavitary Brachytherapy(ICBT) applications alone offer suboptimal coverage in some patients with medial parametrial(<2cms) residual disease after optimization. This retrospective study aims to identify the commonly accommodated size of ovoids in ICBT to identify the dose delivered to the parametrial disease and organs at risk (OARs). Methods: Cancer cervix Patients treated with concurrent chemoradiotherapy and High Dose Rate(HDR) BT of 6-7 Gy in 3-4 fractions prescribed to point A were identified.. Dosimetric details were documented from BT plans. Results : 219 ICBT applications were performed for 142 patients. 115 (52%) with semi-small (20mm), 69 (32%) small (25mm) and 35 (16%) medium (30mm) ovoids. Mean distance of 100% isodose curve obtained by above ovoids were 3.48 ± 0.53cm, 3.57 ± 0.45cm and 3.80 ± 0.44cm respectively (p = 0.005). Point A doses for respective ovoids were 5.40 ± 0.71 Gy, 5.59 ± 0.75 Gy and 5.79 ± 0.70 Gy (p=0.016) and Total Reference Air Kerma(TRAK) was 4137.35 ± 509.35, 4433.60 ± 554.80 and 4604.72 ± 381.45 mGy m2 h-1 (p < 0.001). No significant impact was observed in the OAR doses. Conclusion: Majority of our patients could accommodate semi-small ovoids. This compromises the distance covered by 100% isodose curve at the level of Point A and the dose to medial parametrial disease (<2cms) as well. Such patients may be receive higher dose within medial parametrium by use of Intracavitary + Interstitial Brachytherapy (IC + ISBT) Keywords: Intra-cavitary Brachytherapy, Size of Ovoids |
||
| full article | ||
| 5 | 35-39 | De novo mutation of the RET proto-oncogene revealing multiple endocrine neoplasia type 2A: a sporadic case from Western Algeria |
|
Amina Chami1, Pauline Romanet2, Fatima Mohammedi3, Nadia Benabadji3, Narimane Habour1, Dalia Derkaoui1, Tewfik Sahraoui1 1 Lab. Bio. Dev. Diff. Université Oran 1 Ahmed Ben Bella, Faculté des Sciences de la Nature et de la Vie,
Département de Biologie, Oran, Algérie. |
||
| Abstract | ||
|
Background : Multiple endocrine neoplasia type 2A (MEN2A) is a rare autosomal dominant disorder associated with RET proto-oncogene mutations. Early diagnosis is absolutely critical for managing and preventing aggressive forms of medullary thyroid carcinoma (MTC) and associated tumours. Our aims are to confirm the clinical diagnosis and to detect, in relatives, those who bear the familial mutation in order to benefit from medical management before the first symptoms appear. Case Presentation: We report a sporadic case of MEN2A in a 34-year-old woman from western Algeria. She presented with bilateral medullary thyroid carcinoma and a left pheochromocytoma. Results: Genetic analysis by nextgeneration sequencing revealed a de novo heterozygous c.1901G>C (p.Cys634Ser) mutation in exon 11 of the RET gene. This is a well-known pathogenic variant associated with MEN2A. Discussion: This case proves that RET genetic testing is vital in all cases of MTC, even in those without a family history, as de novo mutations can occur. The absence of this variant in the patient's first-degree relatives confirms the de novo origin, possibly linked to advanced paternal age. Conclusion: Systematic genetic screening and counselling are essential for the early diagnosis and appropriate management of MEN2A, particularly in sporadic cases. Broader implementation of molecular testing and genetic counselling in Algeria is recommended to improve patient outcomes and prevent transmission to future generations. Keywords: MEN2, RET, De Novo Mutation |
||
| full article | ||
| 6 | 40-52 | Predictors of Recurrence and Long-Term Outcomes of Intracranial Meningiomas: A Retrospective Multicenter Study from Saudi Arabia |
|
Afnan Alkhotani1, Rothaina Saeedi1, Haneen Alomar2, Fahad Alghamdi3, Joudah Almaghrabi4, Mohammed Binmahfoodh1, Saleh Baeesa1 1 Department of Neurosciences, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia. |
||
| Abstract | ||
|
Introduction: Meningioma is the second most prevalent primary tumor of the central nervous system. The World Health Organization (WHO) categorizes meningiomas into three grades, with the less frequent higher grades (2 and 3) demonstrating a high local recurrence rate even after complete resection. This study aims to elucidate the tumor recurrence predictors and treatment outcomes associated with various histopathological types of intracranial meningiomas. Methods: A retrospective study was conducted to analyze the electronic medical records of histopathologically confirmed meningioma patients at two tertiary centers in Jeddah, Saudi Arabia, from 2005 to 2015. The primary objective was to delineate the clinical and radiological characteristics associated with various histopathological types of meningioma, as well as to ascertain the longterm outcomes and risk factors for tumor recurrence. Results: A comprehensive review of 255 patients demonstrated a predominance of females (72.9%) and a mean age at presentation of 51.8 years. The follow-up period had a minimum duration of five years. The most prevalent clinical manifestation was headache, occurring in 41.6% of cases. Notably, 90.6% of cases did not exhibit apparent preoperative sensory-motor neurological deficits, while 5.5% presented with marked hemiparesis. The histopathologic pattern predominantly consisted of meningothelial meningioma (47.1%). The overall tumor recurrence rate during follow-up was observed in 26 patients (10.2%). This rate varied depending on the WHO grade: 13 patients (5.1%) with grade 1, 9 patients (3.5%) with grade 2, and 5 patients (1.6%) with grade 3 meningiomas. The recurrence rate exhibited a statistically significant correlation with the extent of resection. Notably, there was a higher recurrence rate associated with Simpson's grade 3 and 4 resections (p<0.008 and <0.003, respectively). The radiological findings, including peritumoral edema (56.2%), midline shift (17.9%), calcification (14.3%), and central necrosis (6.3%), exhibited no significant correlation with recurrence. Notably, there was a substantial correlation between tumor size and the probability of recurrence, with a likelihood ratio of 1.75 (p<0.04). Conclusion : Our study presents comparable findings to international data pertaining to clinical behaviors, radiological, and histopathological characteristics. Its significance lies in underscoring the statistically significant coefficients for recurrence, encompassing WHO grading, extent of resection, and tumor size. Keywords: Intracranial meningioma; Epidemiology; Prognostic factors; Recurrence; Surgery; Outcome; Saudi Arabia. |
||
| full article | ||
| 7 | 53-64 | Quality of Life (QoL) using EORTC QoL-C30 and BN20 among Patients who Underwent Brain Tumor Resection in a Tertiary Care Center in Saudi Arabia |
|
Rana H. Moshref1,2, Leena H. Moshref1, Fatemah A. Alhalawani1, Ahmed AlLawati1, Masaheer A. Aljehani1, Noor M. Shibriq1, Wafa A. Saber1, Ahlam B. Khojah1, Rawan M. Alsayed1, Razan Daghistani3, Khalid M. Bajunaid4, Mohammed A. Alyousef1, Abdulrahman J. Sabbagh1, Saleh S. Baeesa1,2 1 Section of Neurosurgery, Department of Surgery, King Abdulaziz University, Jeddah, Saudi Arabia |
||
| Abstract | ||
|
Introduction: Quality of life (QoL) encompasses the awareness of individuals' well-being in various aspects of their lives, including physical, personal, mental, and social domains. It is imperative to address QoL concerns in patients with brain tumors. The objective of this study is to assess the QoL among brain tumor patients treated a tertiary hospital in Saudi Arabia. Methods: A retrospective study conducted at a single academic institution in 2017 analyzed data from adult patients diagnosed with brain tumors who underwent craniotomy and resection procedures over a 10-year period (2007-2017). The assessment of QoL was conducted employing a translated Arabic questionnaire derived from the European Organization for Research and Treatment of Cancer (EORTC) standardized model (QLQ-C30). This model evaluates various domains, including global health, physical function, role functioning, emotional functioning, cognitive functioning, social functioning, and symptoms domain. Furthermore, the brain cancer model (BN20) was utilized to assess symptoms and evaluate all aspects of well-being. Results: In this study, a total of 76 patients were included, with a median age of 46 years. No gender bias was observed. Meningioma was the most prevalent brain tumor in our study, comprising 40% of the cases, followed by glioma and other types. It is noteworthy that more than half (65%) of the brain tumor patients had a World Health Organization (WHO) grade I brain tumor, while 15% had grade II, and 20% had grades III or IV. Supratentorial was the most common location for brain tumors. In all types of brain tumors, particularly in patients who underwent resection of meningioma and glioma, the QoL scales and measurements of daily functioning consistently exhibited low scores. Better QoL scores were correlated with male gender, the location of the brain tumor, and the WHO tumor grade. Conversely, perioperative headache, drowsiness, neurological deficits, and low socioeconomic status were associated with poor QoL. Conclusion: Our study is the first study reported in Saudi Arabia to evaluate the quality of life of patients undergoing surgical procedures for brain tumors. We demonstrated that the QoL experienced by brain tumor patients consistently appeared to be poor, irrespective of the specific type of tumor. We underscore the paramount significance of evaluating the QoL of brain tumors within the Gulf and Middle East regions. To comprehensively evaluate the QoL of brain tumor patients globally, a substantial sample size and longitudinal or prospective studies are indispensable. Keywords: Quality of life, Brain tumors, WHO grading, QLQ-30, EORTC |
||
| full article | ||
| 8 | 54-65 | Is there a correlation between estrogen receptor expression level and early breast cancer survival? A Retrospective Study. |
|
Ayman Rasmy1,2, Ahmed Zeeneldin3,4, Walid Abozeed5, Saeed Al-Ghamdi2, Shereef Elsamany3,6 1 Medical Oncology, Zagazig University, Egypt |
||
| Abstract | ||
|
Introduction: The optimal cut-off of ER-positivity is still debatable; however, adjuvant hormonal therapy is usually given if ER expression = 1%. The present study aims to assess clinicopathological features and survival outcome of patients with low compared to higher ER expression level. Methods: In this retrospective, we checked nonmetastatic hormonal receptors-positive, HER2 negative breast cancer patients who presented to three Hospitals in Egypt and Saudi Arabia between 2020-2022. Different clinicopathological factors and data of relapse were checked in patients' medical records. These data were compared in patients with ER-Low (1-10%) Vs. ER-High (>10%) expression level. Results:We included 419 patients who met the eligibility criteria of the study. Only 3.3% of patients had ER-Low. Compared to ER-High group, the ER-Low expression were more likely to have grade 3 tumours (64.3% vs. 21.0%, p=<0.0001), PR-negative (64.3% vs. 16.3%, p= <0.0001). Furthermore, younger age (= 50 years) was more frequent in ER-Low group compared to ERHigh patients (71.4% vs. 42.5%, respectively, p=0.032). Likewise, ER-High patients were more likely to have high ER-staining intensity (74.1% vs. 0.0%, p<0.0001). Disease free survival (DFS) was numerically improved in patients with ER-High, but without statistical significance. After adjustment of different clinicopathological prognostic factors, DFS benefit in ER-High group was more definite (HR=3.59, 95% CI 1.11-11.55, p=0.032). Conclusion: ER-low (1-10 %) expression was rare in the study group. Low ER expression was linked with more aggressive features at diagnosis and seems to have worse DFS which was more pronounced after adjustment for different clinic-pathological factors. : |
||
| full article | ||
| 9 | 75-79 | Efficacy and Safety of Paclitaxel Plus Ramucirumab as Second-Line Therapy in Advanced Gastric Cancer: A Retro-Prospective Single-Centre Study |
|
Varun Goe1, Arpit Jain2, Nivedita Patnaik3, Dharmistha Basu2, Shaifali Goel4, Akanksha Jaju5, Vineet Talwar6, Shivendra Singh7 1Senior Consultant, Department of Medical Oncology, Rajiv Gandhi Cancer Hospital, New Delhi, India |
||
| Abstract | ||
|
Background: Advanced gastric cancer (AGC) has limited treatment options beyond first-line therapy. The combination of paclitaxel and ramucirumab is an approved second-line regimen. This study evaluates the real-world efficacy and safety of this combination in Indian patients. Aim: To assess the effectiveness and tolerability of paclitaxel plus ramucirumab in advanced gastric/gastroesophageal junction adenocarcinoma in a real-world setting. Materials and Methods: This retro-prospective study included 85 patients with AGC treated between January 2020 and December 2024 at a tertiary cancer centre in North India. Patients received paclitaxel 80 mg/m² on days 1, 8, and 15, and ramucirumab 8 mg/kg on days 1 and 15 of a 28-day cycle. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Results: The median age was 58 years; 71% were male. ECOG PS 0-1 was present in 70%. Prior gastrectomy was reported in 36%. Median PFS was 5.1 months, and OS was 9.3 months. ORR was 27%, and DCR was 66%. Common grade 3/4 adverse events included neutropenia (19%), neuropathy (13%), and hypertension (9%). Conclusion: Paclitaxel plus ramucirumab is effective and well-tolerated as second-line treatment in Indian AGC patients. Outcomes mirror global data and support its continued use in resource-limited settings. Keywords: Gastric cancer, ramucirumab, paclitaxel, second-line therapy, Indian population, real-world data. |
||
| full article | ||
| 10 | 80-84 | Single Centre Experience of Treating Children with Cancer in the United Arab Emirates |
|
Mehnaz Aabideen1,2, Arya Ashokan11, Sagar Mohan Nivargi1, Mohammed Ramzan1, Deepthi Boddu1, Fouzia Aboobacker1, Abdullah Odat1, Mohammed Taher1, Dr. Rawia Mohamed1, Rajasekhar Cingapagu1, Humaid O. Al Shamsi1,3-7, Zainul Aabideen1 1 Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates |
||
| Abstract | ||
|
Introduction: Cancer is a leading cause of death in children. Advancements in medical sciences have significantly improved childhood cancer outcome. However, the pattern of malignancy and outcomes of childhood cancer in the UAE have not been published in the literature in the recent period. Therefore, we aim to investigate this in a leading cancer institute in Abu Dhabi, United Arab Emirates (UAE). Methodology : This is a retrospective study. We collected data including diagnosis; age at diagnosis; treatments used e.g., chemotherapy, radiation, surgery, immunotherapy and bone marrow transplant (BMT) and outcomes. Overall survival (OS) and Event-Free Survival (EFS) were estimated using the Kaplan Meier method. Results: There are 82 children with cancer. The male-tofemale ratio is 1.2. Most patients (45%) were diagnosed between one to five years of age. The most common malignancies are B cell Acute Lymphoblastic Leukaemia (32, 39%), brain tumours (12, 15%); Neuroblastoma (9, 10%), Hodgkin Lymphoma (8, 9%) and Wilms Tumour (5, 6%); Acute Myeloid Leukaemia (3, 4%); Non-Hodgkin Lymphoma (3, 4%); Ewing Sarcoma (3, 4%); T ALL (2, 2%); Osteosarcoma (2, 2%); Angiosarcoma (1, 1%); Synovial Sarcoma (1, 1%). 28 (34%) of patients had completed all treatment at Burjeel Cancer Institute (BCI); 15 (18%) had completed their treatment at another centre and attending follow-up at BCI; and 5 (6%) commenced their treatment at BCI and were transferred to another centre. 34 (41%) but currently still undergoing treatment at BCI. The abandonment rate is 0%. Overall survival is 94% and event-free survival is 90%. Discussion: The rapid progression of UAE cancer care over the past four decades has contributed massively to our favourable survival outcomes. Radiation therapy, bone marrow stem cell transplantation, strict medication regulation and monitoring by the UAE Department of Health have been established in recent years to further enhance treatment for cancer patients in the UAE. Conclusion: The results of our study are comparable to the international standard. More studies involving multiple centres in the UAE are needed to ascertain the exact pattern of paediatric malignancy and outcomes in the UAE. Keywords: Paediatric Oncology; Leukaemia; Neuroblastoma; Lymphoma |
||
| full article | ||
| 10 | 85-92 | Review Article | Histopathological and Molecular Features of the Mammary Sclerosing Adenosis Lesions and Their association with breast carcinoma: Review of literature |
|
Rabab Ahmed Mohammed1,2, Amina Ismaeel1, Fayek Al Hilli1 1 Department of Pathology, College of Medicine and Health Sciences,
Arabian Gulf University, Manama, Kingdome of Bahrain |
||
| Abstract | ||
|
Sclerosing adenosis (SA) is one of the findings seen in breast biopsies both in symptomatic and asymptomatic patients. Accurate diagnosis of this lesion is sometimes challenging for pathologists and radiologists. The lesion is characterized by proliferation of irregular glands with excess sclerosis in the surrounding stroma giving the lesion the features of invasive carcinomas. Will SA evolve into carcinoma? How long will it take for this transformation to occur? Can we distinguish between lesions that will undergo malignant transformation and those won't? These are all questions that have been raised about SA for years. Management of SA is not a straightforward decision; it differs from patient to another according to several factors. The following review article shed light on the recent updates about SA of the breast, its morphological histopathological characteristics, features that distinguish it from malignant tumors, radiological features, molecular mechanisms underlying this process and its management. Keywords: Sclerosing adenosis, radial scar, breast carcinoma, risk |
||
| full article | ||